Telmisartan treatment ameliorates memory deficits in streptozotocin-induced diabetic mice via attenuating cerebral amyloidosis

Telmisartan,an angiotensin ii type 1-receptor blocker (arbs),has been reported to exert beneficial effects on the central nervous system (cns). however,the effect of telmisartan on cognitive impairment associated with type 1 diabetes is not well known. here,we examined the possibility that telmisartan could improve memory function in a type 1 diabetic mouse model,streptozotocin (stz)-induced diabetic mice. stz-induced diabetic mice subjected to the morris water maze (mwm) task exhibited a significant decline of spatial learning and memory. oral administration of telmisartan at two nonhypotensive doses (0.7 or 0.35 mg/kg) significantly improved memory deficits in stz-induced diabetic mice. telmisartan treatment markedly reduced aβ42,app,bace1,rage,and nf-κb p65 of the hippocampus and cortex,but did not beneficially affect hyperglycemia and hypoinsulinemia in the stz-induced diabetic mice compared with untreated diabetic mice. taken together,our findings suggest that telmisartan ameliorates memory deficits in type 1 diabetic mice,at least partly because of attenuation of amyloidosis in the brain. © the japanese pharmacological society.